Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

Eli M. Roth (Lead / Corresponding author), Marja-Riitta Taskinen, Henry N. Ginsberg, John J. P. Kastelein, Helen M. Colhoun, Jennifer G. Robinson, Laurence Merlet, Robert Pordy, Marie T. Baccara-Dinet

    Research output: Contribution to journalArticlepeer-review

    215 Citations (Scopus)
    328 Downloads (Pure)

    Fingerprint Dive into the research topics of 'Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences